Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.

MLA

Rubino, Manila, et al. “Peptide Receptor Radionuclide Therapy with 177Lu- or 90Y-SSTR Peptides in Malignant Pheochromocytomas (PCCs) and Paragangliomas (PGLs): Results from a Single Institutional Retrospective Analysis.” Endocrine, vol. 84, no. 2, May 2024, pp. 704–10. EBSCOhost, https://doi.org/10.1007/s12020-024-03707-5.

APA

Rubino, M., Di Stasio, G. D., Bodei, L., Papi, S., Rocca, P. A., Ferrari, M. E., Fodor, C. I., Bagnardi, V., Frassoni, S., Mei, R., Fazio, N., Ceci, F., & Grana, C. M. (2024). Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis. Endocrine, 84(2), 704–710. https://doi.org/10.1007/s12020-024-03707-5

Chicago

Rubino, Manila, Giuseppe Danilo Di Stasio, Lisa Bodei, Stefano Papi, Paola Anna Rocca, Mahila Esmeralda Ferrari, Cristiana Iuliana Fodor, et al. 2024. “Peptide Receptor Radionuclide Therapy with 177Lu- or 90Y-SSTR Peptides in Malignant Pheochromocytomas (PCCs) and Paragangliomas (PGLs): Results from a Single Institutional Retrospective Analysis.” Endocrine 84 (2): 704–10. doi:10.1007/s12020-024-03707-5.